Trius Therapeutics Inc 4
4 · Trius Therapeutics Inc · Filed Aug 10, 2010
Insider Transaction Report
Form 4
KPCB PANDEMIC & BIO DEFENSE FUND LLC
10% Owner
Transactions
- Purchase
Common Stock
2010-08-06$5.00/sh+823,906$4,119,530→ 2,377,881 total - Conversion
8% Convertible Promissory Note
2010-08-06−498,394→ 0 total→ Common Stock (498,394 underlying) - Conversion
Series B Preferred Stock
2010-08-06−9,078,000→ 0 total→ Common Stock (1,055,581 underlying) - Conversion
Common Stock
2010-08-06+1,055,581→ 1,055,581 total - Conversion
Common Stock
2010-08-06+498,394→ 1,553,975 total
Footnotes (2)
- [F1]Series B Preferred Stock was converted into shares of the Issuers Common Stock upon the consummation on the Issuer's initial Public Offering on an 8.6 for 1 basis.
- [F2]Principal and accrued interest was converted upon the Issuer's initial public offering into shares of Common Stock at a conversion price of 87.5% of the per share price of the Common Stock sold in the Issuer's initial public offering on August 6, 2010, at $5.00 per share.